Table 5.
Selected marker targeted studies that could enroll PDA patients for targeted interventions
| NCT | Trial Design | N | Target | Sponsor |
|---|---|---|---|---|
| 02079740 | Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors (KRAS mutant tumors) |
130 | MEK BCL2 |
GSK |
| 02230553 | Lapatinib Plus Trametinib in KRAS Mutant Malignancies (M14LTK) |
30 | MEK EGFR |
Netherlands Cancer Institute |
| 02039336 | Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant Malignancies |
35 | MEK EGFR |
Netherlands Cancer Institute |
| 01986166 | A Study of MEHD7945A and Cobimetinib (GDC-0973) in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS |
50 | MEK EGFR |
Genentech |
| 01449058 | A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors |
138 | MEK PI3K |
Novartis |
| 02187783 | LEE-011 for tumors with pathway defects (loss of CDKN2A amplification of CCND1/3 or CDK4/6) SIGNATURE |
90 | CDK4/6 | Novartis |
| 02065063 | Palbociclib in combination with trametinib for solid tumors (Phase 1/2) |
100 | CDK4/6 MEK |
GSK |
| 02022982 | Palbociclib in combination with PD- 0325901 for KRAS mutant tumors (Phase 1) |
30 | CDK4/6 MEK |
Pfizer |
| 01959139 | LGK974 in Patients With Malignancies Dependent on Wnt Ligands |
100 | WNT | novartis |
| 02152254 | IMPACT 2: Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer |
1362 | Multiple | MD Anderson |
| 01827384 | NCI-MPACT: Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors |
700 | DNA repair KRAS PI3K/MTOR |
NCI |
| Pending | NCI-MATCH: Molecular Analysis for Therapy Choice |
1,000 | 20–25 Agents |
NCI |